Facebook Linkedin RSS Twitter Youtube
Home 2012

Amsterdam Molecular Therapeutics

Glybera’s Story Mirrors that of Gene Therapy
Insights

Glybera’s Story Mirrors that of Gene Therapy

Gene Therapy Briefs
Insights

Gene Therapy Briefs

AMT Raises €2.5M but Says Future Still Hangs in the Balance
Genome Editing

AMT Raises €2.5M but Says Future Still Hangs in the Balance

Latest Gene Therapy Disapproval Points to Confusion over Regulatory Setup
Insights

Latest Gene Therapy Disapproval Points to Confusion over Regulatory Setup

CHMP Says AMT’s Lipoprotein Lipase Deficiency Candidate Can’t Yet Be Approved
Genome Editing

CHMP Says AMT’s Lipoprotein Lipase Deficiency Candidate Can’t Yet Be Approved

AMT Receives a Third of €3.3M EU Grant for Clinical Development of Gene Therapy
Genome Editing

AMT Receives a Third of €3.3M EU Grant for Clinical Development of Gene Therapy

AMT Secures Option to License Sanfilippo B Gene Therapy from Institut Pasteur-Led Consortium
Bioprocessing

AMT Secures Option to License Sanfilippo B Gene Therapy from Institut Pasteur-Led Consortium

Amsterdam Molecular Therapeutics Gains Additional Rights to Amgen GDNF Gene
Genome Editing

Amsterdam Molecular Therapeutics Gains Additional Rights to Amgen GDNF Gene

Progenika Gets CE Mark for LPL Gene Chip for Use with AMT’s Gene Therapy
Genome Editing

Progenika Gets CE Mark for LPL Gene Chip for Use with AMT’s Gene Therapy

Amsterdam Molecular Therapeutics Obtains License to AMT-020 for Acute Intermittent Porphyria
News

Amsterdam Molecular Therapeutics Obtains License to AMT-020 for Acute Intermittent Porphyria

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.